UBS Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $475.00

United Therapeutics (NASDAQ:UTHR) had its price objective upped by investment analysts at UBS Group from $415.00 to $475.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price objective indicates a potential upside of 30.36% from the company’s previous close.

Several other equities research analysts have also recently issued reports on UTHR. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. TD Cowen boosted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, December 30th. Finally, Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $378.36.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $2.05 during trading hours on Wednesday, reaching $364.38. 26,994 shares of the company traded hands, compared to its average volume of 198,616. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $417.82. The stock has a market cap of $16.27 billion, a P/E ratio of 16.00, a P/E/G ratio of 1.05 and a beta of 0.57. The firm’s 50-day moving average is $370.72 and its 200-day moving average is $351.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.38 earnings per share. As a group, research analysts predict that United Therapeutics will post 25.22 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the transaction, the chief financial officer now owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. The trade was a 54.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,422 shares of company stock worth $53,498,732. 11.90% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

A number of hedge funds have recently modified their holdings of the company. CWA Asset Management Group LLC bought a new position in United Therapeutics in the fourth quarter worth $1,914,000. Everence Capital Management Inc. bought a new position in United Therapeutics during the fourth quarter worth about $487,000. GAMMA Investing LLC boosted its holdings in United Therapeutics by 29.0% during the fourth quarter. GAMMA Investing LLC now owns 752 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 169 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares during the period. Finally, Lord Abbett & CO. LLC lifted its position in shares of United Therapeutics by 29.7% during the 3rd quarter. Lord Abbett & CO. LLC now owns 201,695 shares of the biotechnology company’s stock worth $72,277,000 after buying an additional 46,170 shares during the period. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.